Trials / Unknown
UnknownNCT03815084
A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors
Clinical Study on the Safety and Efficacy of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Allife Medical Science and Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
clinical study on the safety and efficacy of PD1 combined with dc-Nk in the treatment of solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pd-1 and DC-NK cells | total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 . |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2020-02-01
- Completion
- 2021-02-01
- First posted
- 2019-01-24
- Last updated
- 2019-01-30
Source: ClinicalTrials.gov record NCT03815084. Inclusion in this directory is not an endorsement.